Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningf
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful impro
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy.
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant
3 No-Brainer Stocks to Buy in June
06:00am, Sunday, 02'nd Jun 2024
AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
07:00am, Thursday, 30'th May 2024
AstraZeneca has been a top-performing stock since 2014. Management recently rolled out an $80 billion sales target for 2030.
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
07:00am, Thursday, 30'th May 2024
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th
AstraZeneca started at buy at Goldman, which rates GSK a neutral
06:34am, Thursday, 30'th May 2024
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
04:05pm, Wednesday, 29'th May 2024
HAMILTON, ON and BOSTON , May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as prec
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
11:56am, Wednesday, 29'th May 2024
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
10:07am, Wednesday, 29'th May 2024
AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious.
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
08:06am, Wednesday, 29'th May 2024
AstraZeneca just wrapped up its last strategic plan successfully. It's now setting a new ambition to be completed by 2030.
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
06:08pm, Tuesday, 28'th May 2024
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
10:51am, Monday, 27'th May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CAMBRIDGE, England--(BUSINESS WIRE)--Dato-DXd TL01 OS HLR.
